Nanobiotix S.A.
FRFinancials
Valuation Metrics
Nanobiotix S.A.'s Market Cap is $1.74B. At end of 2025 it was $239M. Ranked #2123 of 3,121 in US market (top 68%), #831 of 1,463 on NASDAQ (top 57%), #151 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 57%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.74B | US#2,123/3,121 Sec#151/266 |
| Revenue | $33M | US#2,802/3,121 Sec#160/266 |
| Net Income | $-27M | US—/3,121 Sec—/266 |
| Total Assets | $80M | US#3,072/3,121 Sec#263/266 |
| Net Assets | $-99M | US#2,968/3,121 Sec#253/266 |
| Employees | 97 | US#2,638/3,121 Sec#183/266 |
| Value | ||
| P/S | 51.95x | US#2,915/3,121 Sec#163/266 |
| FCF Yield | -2.21% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -34.01% | US#2,912/3,121 Sec#167/266 |
| Op. Margin | -36.49% | US#2,661/3,121 Sec#108/266 |
| Financial Health | ||
| Total Debt | $112M | US#2,415/3,121 Sec#117/266 |
| FCF | $-38M | US#2,499/3,121 Sec#107/266 |
| Cash | $62M | US#2,490/3,121 Sec#215/266 |
| Current Ratio | 1.09x | US#2,155/3,121 Sec#254/266 |
| Performance | ||
| 1Y Return | 251.76% | US#44/3,121 Sec#19/266 |
| 1M Return | -12.66% | US#2,671/3,121 Sec#205/266 |
| From 52W High | -37.21% | US#2,382/3,121 Sec#182/266 |
| 1Y MDD | -50.25% | US#2,474/3,121 Sec#182/266 |
| Trading | ||
| Volume | 99,682 shares | US#2,910/3,121 Sec#261/266 |
| Trading Value | $4M | US#2,765/3,121 Sec#234/266 |
| Per Share | ||
| EPS | $-0.56 | US—/3,121 Sec—/266 |
| BPS | $-2.05 | US—/3,121 Sec—/266 |
Company Info
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.